{"id":"https://openalex.org/W1986341479","doi":"https://doi.org/10.1159/000353163","title":"Identifying the Time to Change BCR-ABL Inhibitor Therapy in Patients with Chronic Myeloid Leukemia","display_name":"Identifying the Time to Change BCR-ABL Inhibitor Therapy in Patients with Chronic Myeloid Leukemia","publication_year":2013,"publication_date":"2013-01-01","ids":{"openalex":"https://openalex.org/W1986341479","doi":"https://doi.org/10.1159/000353163","mag":"1986341479","pmid":"https://pubmed.ncbi.nlm.nih.gov/23949495"},"language":"en","primary_location":{"id":"doi:10.1159/000353163","doi":"https://doi.org/10.1159/000353163","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000353163","pdf_url":null,"source":{"id":"https://openalex.org/S182948766","display_name":"Acta Haematologica","issn_l":"0001-5792","issn":["0001-5792","1421-9662"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Acta Haematologica","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049400849","display_name":"Michael Robert Savona","orcid":"https://orcid.org/0000-0003-3763-5504","observed_orcids":["https://orcid.org/0000-0003-3763-5504"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael R. Savona","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, Tenn., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tenn., USA","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019949455","display_name":"Giuseppe Nicola Saglio","orcid":"https://orcid.org/0000-0002-1046-3514","observed_orcids":["https://orcid.org/0000-0002-1046-3514"]},"institutions":[{"id":"https://openalex.org/I55143463","display_name":"University of Turin","ror":"https://ror.org/048tbm396","country_code":"IT","type":"education","lineage":["https://openalex.org/I55143463"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giuseppe Saglio","raw_affiliation_strings":["University of Turin, Orbassano, Turin, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Turin, Orbassano, Turin, Italy","institution_ids":["https://openalex.org/I55143463"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2065,"has_fulltext":true,"cited_by_count":12,"citation_normalized_percentile":{"value":0.16042781,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"130","issue":"4","first_page":"268","last_page":"278"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/chronic-phase","display_name":"chronic phase","score":0.902999997138977},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.7900000214576721},{"id":"https://openalex.org/keywords/bcr-abl-tyrosine-kinase-inhibitors","display_name":"BCR-ABL tyrosine kinase inhibitors","score":0.9750000238418579},{"id":"https://openalex.org/keywords/second-generation-tyrosine-kinase-inhibitors","display_name":"second-generation tyrosine kinase inhibitors","score":0.7919999957084656},{"id":"https://openalex.org/keywords/treatment-switching","display_name":"treatment switching","score":0.4830000102519989},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.8679999709129333},{"id":"https://openalex.org/keywords/imatinib-intolerance","display_name":"imatinib intolerance","score":0.8199999928474426},{"id":"https://openalex.org/keywords/early-response","display_name":"early response","score":0.5350000262260437},{"id":"https://openalex.org/keywords/disease-transformation","display_name":"disease transformation","score":0.6520000100135803}],"concepts":[{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.8938553333282471},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.8167791366577148},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7925376892089844},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6463475227355957},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5270593166351318},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.48233887553215027},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3762054145336151}],"mesh":[{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069439","descriptor_name":"Dasatinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015466","descriptor_name":"Leukemia, Myeloid, Chronic-Phase","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016044","descriptor_name":"Fusion Proteins, bcr-abl","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1159/000353163","doi":"https://doi.org/10.1159/000353163","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000353163","pdf_url":null,"source":{"id":"https://openalex.org/S182948766","display_name":"Acta Haematologica","issn_l":"0001-5792","issn":["0001-5792","1421-9662"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Acta Haematologica","raw_type":"journal-article"},{"id":"pmid:23949495","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23949495","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Acta haematologica","raw_type":"Journal Article"},{"id":"pmh:oai:iris.unito.it:2318/157496","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/2318/157496","pdf_url":null,"source":{"id":"https://openalex.org/S4306400637","display_name":"Institutional Research Information System University of Turin (University of Turin)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I55143463","host_organization_name":"University of Turin","host_organization_lineage":["https://openalex.org/I55143463"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":59,"referenced_works":["https://openalex.org/W1527252739","https://openalex.org/W1968747503","https://openalex.org/W1970012935","https://openalex.org/W1980571402","https://openalex.org/W1983700931","https://openalex.org/W1987702792","https://openalex.org/W2003973314","https://openalex.org/W2012400712","https://openalex.org/W2016953305","https://openalex.org/W2022158208","https://openalex.org/W2028332702","https://openalex.org/W2028959752","https://openalex.org/W2039531591","https://openalex.org/W2039676744","https://openalex.org/W2042794231","https://openalex.org/W2049362295","https://openalex.org/W2050629960","https://openalex.org/W2051728915","https://openalex.org/W2057206328","https://openalex.org/W2057796192","https://openalex.org/W2058576674","https://openalex.org/W2061440903","https://openalex.org/W2068133101","https://openalex.org/W2072834954","https://openalex.org/W2079517811","https://openalex.org/W2091005492","https://openalex.org/W2097799776","https://openalex.org/W2097946794","https://openalex.org/W2105783133","https://openalex.org/W2106266094","https://openalex.org/W2107268345","https://openalex.org/W2110648386","https://openalex.org/W2117569938","https://openalex.org/W2124196948","https://openalex.org/W2126129237","https://openalex.org/W2132150750","https://openalex.org/W2134512113","https://openalex.org/W2135429827","https://openalex.org/W2135620625","https://openalex.org/W2143939343","https://openalex.org/W2149360785","https://openalex.org/W2152713204","https://openalex.org/W2158884958","https://openalex.org/W2162073077","https://openalex.org/W2163773009","https://openalex.org/W2166270808","https://openalex.org/W2166654361","https://openalex.org/W2170356980","https://openalex.org/W2171188310","https://openalex.org/W2183831728","https://openalex.org/W2261840157","https://openalex.org/W2272594879","https://openalex.org/W2344087471","https://openalex.org/W2508058084","https://openalex.org/W2550919857","https://openalex.org/W2558039519","https://openalex.org/W2588448950","https://openalex.org/W2979541317","https://openalex.org/W4253420620"],"related_works":["https://openalex.org/W2113835364","https://openalex.org/W200689174","https://openalex.org/W2143436731","https://openalex.org/W1978514731","https://openalex.org/W1586127326","https://openalex.org/W2111302855","https://openalex.org/W2808074392","https://openalex.org/W2587456463","https://openalex.org/W2076736727","https://openalex.org/W1932347623"],"abstract_inverted_index":{"Many":[0],"patients":[1],"newly":[2],"diagnosed":[3],"with":[4,47],"chronic":[5,10],"myeloid":[6],"leukemia":[7],"in":[8,104],"the":[9,26,61,69,89,94,98],"phase":[11],"(CML-CP)":[12],"respond":[13],"to":[14,30,55,85],"imatinib.":[15],"Those":[16],"experiencing":[17],"imatinib":[18,84],"resistance/intolerance":[19],"require":[20],"alternative":[21],"treatments.":[22],"Delayed":[23],"responses":[24,45,58],"increase":[25],"risk":[27],"of":[28,37,65],"transformation":[29],"advanced":[31],"disease,":[32],"mutation":[33],"development":[34],"and":[35,51,63,92],"loss":[36],"response.":[38],"In":[39],"retrospective":[40],"analyses,":[41],"achieving":[42],"faster,":[43],"deeper":[44],"correlated":[46],"improved":[48],"long-term":[49],"response":[50],"outcome.":[52,70,95],"Changing":[53],"therapy":[54,102],"obtain":[56],"early":[57,101],"may":[59],"improve":[60],"depth":[62],"speed":[64],"response,":[66],"ultimately":[67],"improving":[68],"Although":[71],"trials":[72],"are":[73,76],"ongoing,":[74],"there":[75],"no":[77],"prospective":[78],"data":[79],"indicating":[80],"that":[81],"changing":[82],"from":[83],"later-generation":[86],"inhibitors":[87],"reverses":[88],"inferior":[90],"prognosis":[91],"improves":[93],"We":[96],"describe":[97],"rationale":[99],"behind":[100],"change":[103],"CML-CP.":[105]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}